SOURCE: Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc.

April 27, 2016 08:30 ET

Opexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact

April 28-30, 2016 in Vatican City

THE WOODLANDS, TX--(Marketwired - Apr 27, 2016) -  Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including for multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited to present at Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact, taking place April 28-30, 2016 in Vatican City.

Mr. Warma will join the world's leading cell therapy scientists, physicians, patients, ethicists and leaders of faith, government and philanthropists to discuss the latest cellular therapy breakthroughs and the hope they provide for the future treatment of disease. Mr. Warma's presentation is entitled, "Can T-cells be Used to Treat Neuromyelitis Optica (NMO) and Other Autoimmune Disorders?"

"I am extremely pleased that Opexa is taking part in this global discussion about the importance of immunotherapies and the transformative role they could play in treating life threatening diseases," stated Neil K. Warma, President and Chief Executive Officer of Opexa. "Opexa has been a pioneer in the development of immunotherapies for over a decade. Our lead therapy candidate, Tcelna, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program for the treatment of secondary progressive multiple sclerosis, an area with a serious unmet medical need. It is for patients like these, with limited or no treatment options, that we, as a community, continue to focus on the advancement and development of potentially life changing therapies, and coming together at The Vatican is a step in that direction."

"We're thrilled Neil Warma will be joining us at The Vatican to speak about T-Cells and how they can be used to treat auto-immune disorders," said Dr. Robin Smith, President of The Stem For Life Foundation. "His company, Opexa Therapeutics, has a unique understanding of how cellular therapies can be used to treat a full spectrum of auto-immune disease including neuromyelitis optica (NMO)."

The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact is hosted by The Vatican's Pontifical Council for Culture, the Stem for Life Foundation and STOQ (Science, Theology and the Ontological Quest) Foundation. Moderated by renowned journalists and broadcasted around the world, the 2016 event will have a unique focus on pediatric cancers and rare genetic diseases, as well as diseases that occur with aging. The conference will explore the future and how science, technology, information and communication will allow us to personalize medical solutions to remove inefficiencies, while reducing overall health care costs. The conference will unite people of all races, religious beliefs, cultural and economic backgrounds in a global conversation about the healing potential of cell therapy and the importance of delivering approved therapies to people suffering with debilitating medical conditions around the world.

About Opexa

Opexa is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the same patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016.

For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com or follow company news on Twitter via @OpexaCEO.

The Stem For Life Foundation (SFLF) is the educational and advocacy subsidiary of The Cura Foundation and is devoted to fostering global awareness of the potential for regenerative medicine to treat and cure a range of deadly diseases and debilitating medical conditions, as opposed to merely treating their symptoms. The Foundation stands at the forefront of a fundamental shift away from traditional drug treatment in favor of amplifying the body's natural repair mechanisms to vanquish disease. For more information on The Stem For Life Foundation, please visit http://www.stemforlife.orgTo follow the Vatican event on Twitter, please join the conversation @StemForLife or via the hashtag #UNITETOCURE.

Cautionary Statement Relating to Forward-Looking Information for the Purpose of "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995

Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "expects," "believes," "may," "intends," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as Tcelna® and OPX-212, constitute forward-looking statements. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation our ability to raise additional capital to continue our development programs, our ability to successfully develop potential products such as Tcelna and OPX-212, our ability to obtain, maintain and protect intellectual property rights (including for Tcelna and OPX-212), as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2015 and our Quarterly Reports on Form 10-Q. All forward-looking statements contained in this release speak only as of the date on which they were first made by us, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after such date.

Contact Information